HepatologyFatty Liver

MASH 2026: Building on the First-Ever Approved Therapy

Resmetirom changed everything. Now the race is on for combination therapies and broader eligibility

Published 21 July 2026SR-2026-003

EditorMara Voss

CopywritersEditorial Team

Coming Soon

MASH 2026: Building on the First-Ever Approved Therapy

Resmetirom changed everything. Now the race is on for combination therapies and broader eligibility

Why We Are Covering This

Resmetirom became the first approved MASH therapy in 2024, and a crowded Phase 3 pipeline with semaglutide, efruxifermin, and pegazosatermin now forces every stakeholder to pick a winner. The differentiation question is urgent and unresolved.

What to Expect

You will evaluate the late-stage MASH pipeline against current resmetirom use, understand how payers will assess competing approvals, and identify which mechanisms offer the most durable patient benefit.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-00307/26

Fatty Liver

Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview

A recent review outlines the mechanisms, diagnosis, and management of metabolic dysfunction associated steatotic liver disease (MASLD) in adults.

Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction

Fatty Liver

ENDO 2026

Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction

A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.

Fatty Liver

Alcohol and Sugar: A Dual Metabolic Challenge for Patients

Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.

EASL Congress 2026: Key Trials to Watch in Liver Disease Management

Hepatocellular Carcinoma

EASL 2026

EASL Congress 2026: Key Trials to Watch in Liver Disease Management

EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.

MASH 2026: Building on the First-Ever Approved Therapy

MASH 2026: Building on the First-Ever Approved Therapy

Be first when this report publishes

Related Articles